6-bromo-N4-[(4-methoxyphenyl)methyl]pyridine-3,4-diamine | 1184843-63-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 6-bromo-N4-[(4-methoxyphenyl)methyl]pyridine-3,4-diamine
• 英文别名: N4-(4-methoxybenzyl)-6-bromopyridine-3,4-diamine；6-bromo-4-N-[(4-methoxyphenyl)methyl]pyridine-3,4-diamine
• CAS: 1184843-63-7
• 化学式: C₁₃H₁₄BrN₃O
• 分子量: 308.178
• InChiKey: USJZRBIDEQXVRD-UHFFFAOYSA-N

物化性质

• 沸点：
  470.6±45.0 °C(Predicted)
• 密度：
  1.501±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  60.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-bromo-N4-[(4-methoxyphenyl)methyl]pyridine-3,4-diamine 在 zinc chloride-2,2,6,6-tetramethylpiperidin-1-ide lithium chloride complex 、 potassium carbonate 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 21.42h， 生成 1-[5-fluoro-6-[1-[(4-methoxyphenyl)methyl]-2-oxo-3-(2,2,3,3,3-pentafluoropropyl)imidazo[4.5-c]pyridin-6-yl]-1-oxido-pyridin-1-ium-3-yl]cyclopropanecarbonitrile
  参考文献：
  名称：

  [EN] PESTICIDALLY ACTIVE SUBSTITUTED 1,3-DIHYDRO-2H-IMIDAZO[4,5-C]PYRIDIN-2-ONE DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS
  [FR] DÉRIVÉS DE 1,3-DIHYDRO-2H-IMIDAZO[4,5-C]PYRIDIN-2-ONE SUBSTITUÉS À ACTION PESTICIDE COMPRENANT DES SUBSTITUANTS CONTENANT DU SOUFRE

  摘要：

  式（I）中的化合物，其中取代基如权利要求1所定义。此外，本发明涉及包括式（I）化合物的农药组合物，以及这些组合物的制备，以及在农业或园艺中使用这些化合物或组合物来对抗、预防或控制动物害虫，包括节肢动物，特别是昆虫、线虫、软体动物或螨类。

  公开号：

  WO2021213929A1
• 作为产物：
  描述：

  2,4-二溴-5-硝基吡啶 在 乙醇 、 N,N-二异丙基乙胺 、 tin(ll) chloride 作用下， 以 四氢呋喃 为溶剂， 反应 9.0h， 生成 6-bromo-N4-[(4-methoxyphenyl)methyl]pyridine-3,4-diamine
  参考文献：
  名称：

  [EN] PESTICIDALLY ACTIVE SUBSTITUTED 1,3-DIHYDRO-2H-IMIDAZO[4,5-C]PYRIDIN-2-ONE DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS
  [FR] DÉRIVÉS DE 1,3-DIHYDRO-2H-IMIDAZO[4,5-C]PYRIDIN-2-ONE SUBSTITUÉS À ACTION PESTICIDE COMPRENANT DES SUBSTITUANTS CONTENANT DU SOUFRE

  摘要：

  式（I）中的化合物，其中取代基如权利要求1所定义。此外，本发明涉及包括式（I）化合物的农药组合物，以及这些组合物的制备，以及在农业或园艺中使用这些化合物或组合物来对抗、预防或控制动物害虫，包括节肢动物，特别是昆虫、线虫、软体动物或螨类。

  公开号：

  WO2021213929A1

文献信息

• [EN] BICYCLYLARYL-ARYL-AMINE COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS DE TYPE BICYCLYLARYL-ARYL-AMINE ET LEUR UTILISATION
  申请人：CANCER REC TECH LTD

  公开号：WO2009103966A1

  公开（公告）日：2009-08-27

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain bicyclylaryl-aryl-amines compounds of the following formula (referred to herein as BCAA compounds), which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or TS inhibitor; (d) a microtubule targeted agent; and (e) ionising radiation: (I).

  本发明一般涉及治疗化合物领域，更具体地涉及以下式（以下简称BCAA化合物）的某些双环芳基芳基胺化合物，该化合物在某些情况下抑制检查点激酶1（CHK1）激酶功能。本发明还涉及包含这种化合物的药物组合物，以及利用这种化合物和组合物在体内外抑制CHK1激酶功能，并用于治疗由CHK1介导的疾病和症状，通过抑制CHK1激酶功能得到缓解等，包括增殖性疾病如癌症等，可选地与另一药剂组合使用，例如，（a）DNA拓扑异构酶I或II抑制剂；（b）DNA损伤剂；（c）抗代谢物或TS抑制剂；（d）微管靶向药物；和（e）电离辐射。
• Bicyclylaryl-aryl-amine compounds and their use
  申请人：Collins Ian

  公开号：US08530468B2

  公开（公告）日：2013-09-10

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain bicyclylaryl-aryl-amines compounds of the following formula (referred to herein as BCAA compounds), which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or TS inhibitor; (d) a microtubule targeted agent; and (e) ionising radiation:

  本发明涉及治疗化合物领域，更具体地涉及以下式子（称为BCAA化合物）的某些双环芳基-芳胺化合物，其抑制检查点激酶1（CHK1）激酶功能。本发明还涉及包含这些化合物的制药组合物，以及使用这些化合物和组合物在体内外抑制CHK1激酶功能，以及治疗由CHK1介导的疾病和病症，通过抑制CHK1激酶功能来改善这些病症，包括增殖性疾病如癌症等，可选择与另一种药物联合使用，例如（a）DNA拓扑异构酶I或II抑制剂；（b）DNA损伤剂；（c）抗代谢物或TS抑制剂；（d）微管靶向药物；以及（e）电离辐射。
• BICYCLYLARYL-ARYL-AMINE COMPOUNDS AND THEIR USE
  申请人：Collins Ian

  公开号：US20100331328A1

  公开（公告）日：2010-12-30

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain bicyclylaryl-aryl-amines compounds of the following formula (referred to herein as BCAA compounds), which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or TS inhibitor; (d) a microtubule targeted agent; and (e) ionising radiation:

  本发明涉及治疗化合物领域，更具体地涉及以下公式（在此称为BCAA化合物）的某些双环芳基-芳基胺化合物，该化合物等可抑制检查点激酶1（CHK1）激酶功能。本发明还涉及包含这种化合物的制药组合物，以及使用这种化合物和组合物在体内外抑制CHK1激酶功能，以及治疗由CHK1介导、通过抑制CHK1激酶功能改善的疾病和情况，包括增生性疾病如癌症等，可选择与另一种药物联合使用，例如：（a）DNA拓扑异构酶I或II抑制剂；（b）DNA损伤剂；（c）抗代谢物或TS抑制剂；（d）微管靶向剂；和（e）电离辐射。
• Structure-Guided Evolution of Potent and Selective CHK1 Inhibitors through Scaffold Morphing
  作者：John C. Reader、Thomas P. Matthews、Suki Klair、Kwai-Ming J. Cheung、Jane Scanlon、Nicolas Proisy、Glynn Addison、John Ellard、Nelly Piton、Suzanne Taylor、Michael Cherry、Martin Fisher、Kathy Boxall、Samantha Burns、Michael I. Walton、Isaac M. Westwood、Angela Hayes、Paul Eve、Melanie Valenti、Alexis de Haven Brandon、Gary Box、Rob L. M. van Montfort、David H. Williams、G. Wynne Aherne、Florence I. Raynaud、Suzanne A. Eccles、Michelle D. Garrett、Ian Collins

  DOI：10.1021/jm2007326

  日期：2011.12.22

  Pyrazolopyridine inhibitors with low micromolar potency for CHK1 and good selectivity against CHK2 were previously identified by fragment-based screening. The optimization of the pyrazolopyridines to a series of potent and CHK1-selective isoquinolines demonstrates how fragment-growing and scaffold morphing strategies arising from a structure-based understanding of CHK1 inhibitor binding can be combined to successfully progress fragment-derived hit matter to compounds with activity in vivo. The challenges of improving CHK1 potency and selectivity, addressing synthetic tractability, and achieving novelty in the crowded kinase inhibitor chemical space were tackled by multiple scaffold morphing steps, which progressed through tricyclic pyrimido[2,3-b]azaindoles to N-(pyrazin-2-yl)pyrimidin-4-amines and ultimately to imidazo[4,5-c]pyridines and isoquinolines. A potent and highly selective isoquinoline CHK1 inhibitor (SAR-020106) was identified, which potentiated the efficacies of irinotecan and gemcitabine in SW620 human colon carcinoma xenografts in nude mice.
• US8530468B2
  申请人：——

  公开号：US8530468B2

  公开（公告）日：2013-09-10